UK: Obviousness And Discoveries From Routine Testing: UK Supreme Court Decides Correct Approach

Last Updated: 14 May 2019
Article by Paul A. Harris and David Pountney

The UK Supreme Court has handed down its judgement in Actavis v ICOS [2019] UKSC 15 unanimously upholding the earlier decision of the Court of Appeal that the patent to a specific dosage regimen of tadalafil was obvious. However, in doing so the UK Supreme Court has allayed the concerns of innovators and big pharma by confirming there is no automatic bar to dosage claim discoveries, made through well-established or routine procedures provided they involve an inventive step.

Background to the dispute

This case concerned the dosage patent EP(UK) 1,173,181 (the '181 Patent') and in particular claims relating to a specific low 5mg dose of the drug tadalafil marketed under the brand name CIALIS and used to treat erectile dysfunction or 'ED'. The CIALIS drug is a competitor (second in class) of the well-known branded drug VIAGRA. However, VIAGRA had certain side effects. Both tadalafil and sildenafil, the active ingredients in VIAGRA, are inhibitors and work by blocking phosphodiestaerase, which otherwise would lead to failure of the dilation of blood vessels.

The 181 Patent is owned by ICOS and is exclusively licensed to Eli Lilly. During pre-clinical and clinical studies, Eli Lilly found that a daily low oral dose of 5mg was therapeutically effective, and minimised the adverse reactions of using the VIAGRA drug.

The decisions of the lower courts

Actavis and others (being generic companies) sought to revoke the 181 Patent to clear the way before their own generic product launches. The main attack was lack of novelty and inventive step (with priority, added matter and insufficiency included in the attack) over the nearest prior art (the 'Daugan Patent'), which disclosed a class of compounds including tadalafil for treating ED. The Daugan Patent had disclosed doses of tadalafil in the range of 0.5 to 800mg but only provided data for a 50mg dose and not a 5mg dose. A key issue was whether routine dose-ranging studies required for clinical development and regulatory approval would have ordinarily extended to the 5mg dose, and so involved an inventive step.

ICOS argued that the low dose would not have been obvious before conducting the Phase II trials, and counterclaimed for infringement.

In the High Court, Mr. Justice Birss considered that the results of the clinical studies were not predictable in advance. He accepted expert evidence that it was not established that the skilled team would always seek to identify the minimum effective dose of a particular drug. Accordingly, the 5mg daily dose was not obvious, and involved an inventive step.

The Court of Appeal disagreed and overturned the High Court's decision. Lord Justice Kitchin (as he then was) held that the Daugan Patent would have motivated the skilled team to conduct clinical dosing studies and discover the low 5mg dose, and so the 181 Patent was obvious.

In reaching this conclusion, Lord Justice Kitchin explained how drug discovery is an iterative process, progressing from one phase to another based on the results of the preceding phase. So long as the skilled team continues to be motivated along the development pathway with an expectation of successfully concluding each stage, then consequently there can be no invention. In this case, the finding along the way of the reduced side effects associated with the low dose was simply a bonus in following the obvious-to-try clinical development, and so did not constitute an inventive step.

The decision of the UK Supreme Court

The appeal raised two main issues: first, how does the test for inventive step apply to a dosage patent resulting from routine testing; and second, was the Court of Appeal entitled to interfere with Mr. Justice Birss' assessment of obviousness and reverse his finding?

In addressing the first issue the UK Supreme Court restated and reviewed the approach to be taken to obviousness, both in the UK courts (which use the re-stated Windsurfing test in Pozzoli SPA v BDMO SA [2007] EWCA Civ 588) and in the EPO (which uses the 'problem solution' approach). ICOS and Eli Lilly argued that the Court of Appeal's approach to obviousness had gone further than required. However, Lord Hodge (giving the sole judgment of the Court) set out a non-exhaustive list of factors to be considered in an obviousness assessment, but cautioned they should not be applied in a mechanistic way. These are:

  • Was it 'obvious to try';
  • Was the research that was conducted routine in nature;
  • The burden and cost of the research;
  • The necessity for, and the nature of, the value judgments the skilled team would have made in the course of a testing program;
  • The existence of alternative or multiple paths of research;
  • The motivation of the skilled person;
  • Whether the results are unexpected or surprising (expectation of success);
  • Hindsight, which includes knowledge of the invention, should not be used;
  • Whether a feature is an added benefit in context (a bonus), or obvious for another purpose;
  • Of particular relevance to this case, the fact that claims to dosage regimens have been held valid, drafted as either Swiss-type or EPC 2000 claims.

The UK Supreme Court upheld the decision of the Court of Appeal that all of the claims lacked an inventive step. It agreed with the Court of Appeal's finding on the logical sequence of testing that, on the facts, the skilled team would use routine, established practices involved in pharmaceutical research, and that the Daugan Patent would have motivated them to identify the low dose. In doing so, the Court cautioned that this was "only one of several factors to be weighed in the assessment and it has no primacy and certainly no paramount status as a consideration."

However, the UK Supreme Court rejected Actavis' argument that "the skilled person's repertoire" should include all obvious modifications or additions to the state of the art. The Court considered such an approach may prevent protection being obtained for selection or improvement patents.

On the issue of whether the Court of Appeal could interfere with the trial judge's decision, the UK Supreme Court held that the trial judge had erred in principle by failing to appreciate that having identified a therapeutic plateau, the skilled team would have continued to test lower dosages until coming upon the 5mg dose. Accordingly, the Court of Appeal had been right to re-weigh the relevant factors and interfere with the trial judge's factual findings.

Finally, it is interesting to note that the UK Supreme Court discussed how the decisions of foreign courts were not necessarily helpful in determining the issues before it, due to potential differences in evidence and the approach to which that evidence may be tested in different courts. Where this leads to will be monitored carefully, since previously the English Courts have striven to be harmonised with the approaches and case outcomes in other EPC jurisdictions (and the EPO Technical Boards of Appeal).


Whilst this decision is disappointing news for the patentees in this case, the UK Supreme Court's decision should provide some reassurance to the wider innovative pharmaceutical industry. Lord Hodge explicitly stated that "...efficacious drugs discovered by research involving standard pre-clinical and clinical tests should be rewarded with a patent if they meet the statutory tests."

The decision is a useful reminder of the factors to be considered when assessing obviousness, but emphasises how the approach should not be a mechanistic one: the relevant factors will depend on each case's specific facts. What will be particularly interesting in the future is to see how this applies to pharmaceutical drug discovery and clinical development, particularly with automation and artificial intelligence playing an ever increasing role.

The full decision from the UK Supreme Court can be read here, the decision of the Court of Appeal here, and the decision at first instance here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions